SCHEDULE 13G

Amendment No. 0 
SYNTA PHARMACEUTICALS CORP 
Common Stock 
Cusip #87162T206 

Cusip #87162T206 
Item 1: Reporting Person - FMR LLC
Item 4: Delaware
Item 5: 3,293,890 
Item 6: 0 
Item 7: 6,493,800 
Item 8: 0 
Item 9: 6,493,800 
Item 11:        10.491% 
Item 12:            HC

Cusip #87162T206  
Item 1: Reporting Person - Edward C. Johnson 3d 
Item 4: United States of America
Item 5: 0 
Item 6: 0 
Item 7: 6,493,800 
Item 8: 0 
Item 9: 6,493,800 
Item 11:        10.491% 
Item 12:        IN 

SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Item 1(a).      Name of Issuer: 

SYNTA PHARMACEUTICALS 
CORP 

Item 1(b).      Name of Issuer's Principal Executive Offices:

45 Hartwell Ave  
Lexington, MA  02421
USA  

Item 2(a).      Name of Person Filing: 

FMR LLC

Item 2(b).      Address or Principal Business Office or, if None, 
Residence:

82 Devonshire Street, Boston, 
Massachusetts  02109

Item 2(c).      Citizenship:

Not applicable

Item 2(d).      Title of Class of Securities:

Common Stock 

Item 2(e).      CUSIP Number:  

87162T206 

Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) 
and the person filing, FMR LLC, is a parent holding company 
in accordance with Section 240.13d-1(b)(ii)(G).  (Note:  See 
Item 7).

Item 4. Ownership

(a)     Amount Beneficially Owned:      6,493,800 

(b)     Percent of Class:       10.491% 

(c)     Number of shares as to which such 
person has:  

(i)     sole power to vote or to direct 
the vote:       3,293,890 

(ii)    shared power to vote or to 
direct the vote:        0 

(iii)   sole power to dispose or to 
direct the disposition of:      6,493,800 

(iv)    shared power to dispose or to 
direct the disposition of:      0 

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another 
Person.

Various persons have the right to receive or the power to 
direct the receipt of dividends from, or the proceeds from the 
sale of, the Common Stock of SYNTA 
PHARMACEUTICALS CORP.  No one person's interest in 
the Common Stock of SYNTA PHARMACEUTICALS 
CORP is more than five percent of the total outstanding 
Common Stock.

Item 7. Identification and Classification of the Subsidiary Which 
Acquired the Security Being Reported on By the Parent 
Holding Company.

See attached Exhibit A. 

Item 8. Identification and Classification of Members of 
the Group.

Not applicable.  See attached Exhibit A. 

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10.        Certification.  

By signing below I certify that, to the best of my knowledge 
and belief, the securities referred to above were acquired in the 
ordinary course of business and were not acquired for the 
purpose of and do not have the effect of changing or 
influencing the control of the issuer of such securities and 
were not acquired in connection with or as a participant in any 
transaction having such purpose or effect.     

Signature

After reasonable inquiry and to the best of my knowledge and 
belief, I certify that the information set forth in this statement 
is true, complete and correct. 

December 10, 2012                       
Date

/s/ Scott C. Goebel                    
Signature

Scott C. Goebel                         
Duly authorized under Power of Attorney
effective as of June 1, 2008 by and on behalf of FMR LLC 
and its direct and indirect  subsidiaries

SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Pursuant to the instructions in Item 7 of Schedule 13G, 
Fidelity Management & Research Company ("Fidelity"), 82 
Devonshire Street, Boston, Massachusetts 02109, a wholly-
owned subsidiary of FMR LLC and an investment adviser 
registered under Section 203 of the Investment Advisers Act 
of 1940, is the beneficial owner of 3,199,910 shares or 5.169% 
of the Common Stock outstanding of SYNTA 
PHARMACEUTICALS CORP  ("the Company") as a result 
of acting as investment adviser to various investment 
companies registered under Section 8 of the Investment 
Company Act of 1940.

Edward C. Johnson 3d and FMR LLC, through its 
control of Fidelity, and the funds each has sole power to 
dispose of the 3,199,910 shares owned by the Funds.

Members of the family of Edward C. Johnson 3d, 
Chairman of FMR LLC, are the predominant owners, directly 
or through trusts, of Series B voting common shares of FMR 
LLC, representing 49% of the voting power of FMR LLC.  
The Johnson family group and all other Series B shareholders 
have entered into a shareholders' voting agreement under 
which all Series B voting common shares will be voted in 
accordance with the majority vote of Series B voting common 
shares.  Accordingly, through their ownership of voting 
common shares and the execution of the shareholders' voting 
agreement, members of the Johnson family may be deemed, 
under the Investment Company Act of 1940, to form a 
controlling group with respect to FMR LLC.

Neither FMR LLC nor Edward C. Johnson 3d, 
Chairman of FMR LLC, has the sole power to vote or direct 
the voting of the shares owned directly by the Fidelity Funds, 
which power resides with the Funds' Boards of Trustees.  
Fidelity carries out the voting of the shares under written 
guidelines established by the Funds' Boards of Trustees.

Pyramis Global Advisors, LLC ("PGALLC"), 900 
Salem Street, Smithfield, Rhode Island, 02917, an indirect 
wholly-owned subsidiary of FMR LLC and an investment 
adviser registered under Section 203 of the Investment 
Advisers Act of 1940, is the beneficial owner of 29,160 shares 
or 0.047% of the outstanding Common Stock of SYNTA 
PHARMACEUTICALS CORP as a result of its serving as 
investment adviser to institutional accounts, non-U.S. mutual 
funds, or investment companies registered under Section 8 of 
the Investment Company Act of 1940 owning such shares.

Edward C. Johnson 3d and FMR LLC, through its 
control of PGALLC, each has sole dispositive power over 
29,160 shares and sole power to vote or to direct the voting of 
29,160 shares of Common Stock owned by the institutional 
accounts or funds advised by PGALLC as reported above.

Pyramis Global Advisors Trust Company ("PGATC"), 
900 Salem Street, Smithfield, Rhode Island, 02917, an indirect 
wholly-owned subsidiary of FMR LLC and a bank as defined 
in Section 3(a)(6) of the Securities Exchange Act of 1934, is 
the beneficial owner of 3,264,730 shares or 5.274% of the 
outstanding Common Stock of the SYNTA 
PHARMACEUTICALS CORP as a result of its serving as 
investment manager of institutional accounts owning such 
shares.

Edward C. Johnson 3d and FMR LLC, through its 
control of Pyramis Global Advisors Trust Company, each has 
sole dispositive power over 3,264,730 shares and sole power 
to vote or to direct the voting of 3,264,730 shares of Common 
Stock owned by the institutional accounts managed by 
PGATC as reported above.

SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
RULE 13d-1(f)(1)  AGREEMENT

The undersigned persons, on December 10, 2012, agree 
and consent to the joint filing on their behalf of this Schedule 
13G in connection with their beneficial ownership of the 
Common Stock of SYNTA PHARMACEUTICALS CORP at 
December 01, 2012.

FMR LLC

By /s/ Scott C. Goebel                  
Scott C. Goebel
Duly authorized under Power of Attorney effective as 
of June 1, 2008, by and on behalf of FMR LLC and its direct 
and indirect subsidiaries

Edward C. Johnson 3d

By /s/ Scott C. Goebel                  
Scott C. Goebel
Duly authorized under Power of Attorney effective as 
of June 1, 2008, by and on behalf of Edward C. Johnson 3d

Fidelity Management & Research Company

By /s/ Scott C. Goebel                  
Scott C. Goebel
Senior V.P. and General Counsel

Pyramis Global Advisors Trust Company

By /s/ Ashling Kanavos                  
Ashling Kanavos
Duly authorized under Power of Attorney
dated April 6, 2009, by William E. Dailey
Senior Vice President
and Chief Financial Officer